Morgan Stanley Innate Pharma Sa Call Options Transaction History
Morgan Stanley
- $1.49 Trillion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding IPHA
# of Institutions
11Shares Held
98.7KCall Options Held
0Put Options Held
0-
Ken Griffin Citadel Advisors LLC | Chicago, Il26.6KShares$56,6940.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny11.7KShares$24,8370.0% of portfolio
-
Ubs Group Ag5.96KShares$12,6880.0% of portfolio
-
Gamma Investing LLC Foster City, CA2.28KShares$4,8580.0% of portfolio
-
Rhumbline Advisers Boston, MA470Shares$1,0010.0% of portfolio
About Innate Pharma SA
- Ticker IPHA
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 79,893,000
- Market Cap $170M
- Description
- Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and periphera...